Press Room

Event

Drug Delivery to the Lungs - DDL25

Start
Wednesday, December 10, 2014 - 00:00
End
Friday, December 12, 2014 - 00:00
Location: Edinburgh, Scotland, UK
Booth Number: 36 A

DDL25 will be held from Wednesday 10th December until Friday 12th December 2014 at the Edinburgh International Conference Centre, Edinburgh, Scotland, UK. Hovione will be present with a booth (36 A) and a set of posters.

Contact us if you would like to schedule a meeting or to find more about the Hovione posters at DDL.

contact us button | Hovione
http://go.hovione.com/l/47122/2014-11-20/27k8p

 

HOVIONE POSTERS

Respiratory targeting: Drug-alone Formulations enabled by Particle Engineering
Nick Barker, Gaauri Naik, Sofia Silva & Eunice Costa

Screening and Optimization of Formulation and Process Parameters for the Manufacture of Inhalable Composite Particles by Spray-drying
Cláudia Moura, João Vicente, Maria Palha, Filipe Neves, Ana Aguiar-Ricardo & Eunice Costa

On the performance of coarse and fine lactose blends for DPIs: Part A – rheology behavior
Filipa M. Maia, Maria Palha, Isabel S. Lopes & Filipe Neves

On the performance of coarse and fine lactose blends for DPIs: Part B - capsule filling and device performance
Maria Palha, Filipa M. Maia, João V. Fernandes & Filipe Neves

The Influence of the Formulation and Delivery Approach on the Aerodynamic Performance of Salmeterol Xinafoate
Cláudia Moura, Sofia Silva, Filipe Neves, Ana Aguiar-Ricardo & Eunice Costa

 

DOWNLOAD POSTERS
The posters will be available after the conference and by pre-registration only. To assure that you get your copy, complete the pre-registration below.

pre-register button | Hovione
http://go.hovione.com/l/47122/2014-11-12/24t31

Also in the Press Room

See All

CDMO Hovione and biotechnology company Firstgene Life Sciences (of Xlife Sciences) have collaborated to advance Hovione’s drug delivery platform for the targeted treatment of Hepatocellular Carcinoma (HCC). “We are proud to advance the development of innovative oncology treatments that address a critical unmet need for precision gene expression at the tissue level,” said Hovione CEO Dr Jean-Luc Herbeaux. The virus-like particle technology will be engineered and functionalised for the specific carcinoma cell type using therapeutically validated AAVs, including a novel primer compound. Hovione will be responsible for molecular engineering, the supply of tailor-made virus-like particles and the execution of proof-of-concept studies. “HCC, the most common liver cancer and a leading cause of cancer-related death, continues to represent a major unmet medical need,” said Firstgene managing director Dr Alexander Zink. “The combination of Hovione’s expertise in complex chemistry and particle engineering and the commercialisation expertise of Xlife Sciences positions Firstgene well to offer patients potential new safe and effective therapy options.”   Read the full article at scientistlive.com    

Press Clipping
Scientist Live, 12 May 2025

Partnership advances liver cancer treatment

May 12, 2025

Dear Customer, As you may be aware, Portugal and Spain experienced yesterday, April 28 (at approximately 11:30) a widespread power outage. This unexpected event, beyond our control, affected the normal activities at our sites in Portugal. In response, we promptly activated our contingency protocols for this type of situation, prioritizing the safety of facilities and personnel. All ongoing processes were taken to safe hold points, and no new processes were initiated. Our backup power generators ensured continuity of critical functions throughout the duration of the outage, which lasted approximately 11 hours, until the power from the grid was restored at the site. The site began resuming operations gradually through the night making sure all systems being restarted safely and verified to be in good working conditions. We anticipate that most activities will be fully resumed during today. Should you have any specific questions regarding your product or project, we kindly encourage you to contact your Account Manager or Project Manager, who will be glad to assist you. We sincerely appreciate your understanding and continued partnership.      

News
News release, 29 April 2025

Widespread power outage in Portugal - Message to our clients

Apr 29, 2025

In a recent appearance on CNN Portugal’s Pitch – Brand & Content program, Ilda Ventura, Senior Vice President of Human Resources at Hovione, highlighted a powerful reality: 55% of our employees in Science, Technology, Engineering, and Mathematics (STEM) roles are women. At Hovione, we’re proud to foster an environment where women in science thrive - leading innovation, driving progress, and shaping the future of healthcare. But our commitment goes beyond numbers - it’s about creating the right conditions for scientific talent to grow, equally and globally. “I am proud to say that, in our company, there is no gender pay gap between men and women. We empower everyone. Our female and male scientists are all working to find more sustainable, faster, and more productive ways to achieve victories over diseases.” - Ilda Ventura Watch the full edition to learn more about our commitment to women in science at CNNPortugal.pt  (Language: Portuguese)  

Press Clipping
CNN Portugal, 15 March 2025

Ilda Ventura broadcasted on CNN Portugal

Mar 15, 2025

Also in Events

See All